Highlights:

• Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial
• Publication in Movement Disorders demonstrates that ATH434 reduces α–synuclein related neurodegeneration in MSA animal model
• Presents to MST Access Australian Micro & Small Caps Conference
• Cash balance at 30 June 2021 of A$28M

MELBOURNE,...